You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.
The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.
AMA's suggestions include increasing transparency about testing capacity and providing guidance on serology tests, among other things.
The additional funds will be used to advance the development of the company's Next Generation Phenotyping technology through clinical trials.
The funding will support validation of an assay for both manual and high-throughput automated workflows.
Under the Public Readiness and Emergency Preparedness Act, pharmacists qualify as "covered persons" to administer SARS-CoV-2 tests.
The hospitals said they weren't able to keep up with testing demand because they didn't have complete kits or the individual supplies to perform tests.
Some of the supplemental will go toward the purchase of lab equipment, supplies, staffing, shipping, and other resources, HHS said.
The Aries SARS-CoV-2 assay provides results in approximately two hours and can be run on Luminex's sample-to-answer Aries Systems.
The test is the fourth COVID-19 molecular diagnostic to be awarded funding from BARDA. Others include Hologic, Qiagen, and DiaSorin Molecular.